GILEAD SCIENCES, INC. 8-K

What Happened

• Gilead Sciences, Inc. held its 2026 Annual Meeting on April 30, 2026 and filed an 8‑K reporting the results. Of 1,241,222,013 shares entitled to vote, 1,130,179,690 were represented (quorum).
• Nine directors were elected to serve for the coming year (all nominees were elected). The filing includes individual vote tallies for each director. The company also ratified Ernst & Young LLP as its independent registered public accounting firm and reported approval of the amended and restated 2022 Equity Incentive Plan and the advisory vote on executive compensation (say‑on‑pay).

Key Details

• Shares entitled to vote: 1,241,222,013; shares represented at start of meeting: 1,130,179,690.
• Director elections: nine directors elected; notable tallies include Daniel P. O’Day (980,597,212 For; 50,179,985 Against; 4,394,880 Abstentions); other directors received over 990 million For votes.
• Auditor ratification: Ernst & Young LLP ratified (For: 1,046,350,569; Against: 82,831,295; Abstain: 998,602).
• Governance votes: Say‑on‑pay approved (For: 954,325,805; Against: 77,503,947; Abstain: 3,342,325; Broker non‑votes: 95,008,389). Amended 2022 Equity Incentive Plan approved (For: 970,290,586; Against: 62,501,433; Abstain: 2,380,058).
• Stockholder proposals failed by wide margins: independent Board Chair (For: 280,044,780; Against: 752,716,225), report on extended patent exclusivities (For: 134,042,210; Against: 886,986,584), and report on ESG/DEI compensation metrics (For: 7,262,421; Against: 1,022,330,186). Broker non‑votes on these items: 95,008,389.

Why It Matters

• Board and governance continuity: Re‑election of all nine directors keeps current leadership and strategy in place. Investors can expect consistency in board oversight and decision‑making for the coming year.
• Compensation and equity plan approvals: Say‑on‑pay support and approval of the amended 2022 Equity Incentive Plan allow Gilead to continue executive compensation practices and grant equity awards under the updated plan, which can affect dilution and executive incentives.
• Auditor continuity: Ratification of Ernst & Young maintains accounting firm continuity for fiscal 2026.
• Stockholder sentiment: Large margins against the three shareholder proposals indicate limited investor support for changes such as an independent board chair or additional reports on patent exclusivity and ESG/DEI compensation metrics.